Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 3/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13345438 | 1.00 | ADRB2 (0.38) | ADRB2ADRB1ADRB3CYP3A4HTT | |
| SCHEMBL7870032 | 1.00 | ADRB2 (0.38) | ADRB2ADRB1ADRB3CYP3A4HTT | |
| SCHEMBL29064066 | 0.87 | MMP12 (0.37) | ADRB2ADRB1ADRB3CYP3A4HTT | |
| SCHEMBL9735944 | 0.87 | MMP12 (0.37) | ADRB2ADRB1ADRB3CYP3A4HTT | |
| SCHEMBL14551600 | 0.86 | KCNA5 (0.40) | CYP3A4HTTSMN1; SMN2KCNA5POLB | |
| SCHEMBL9736771 | 0.85 | ADRB2 (0.36) | ADRB2ADRB1ADRB3CYP3A4HTT | |
| SCHEMBL13345392 | 0.85 | HTT (0.35) | CYP3A4HTTSMN1; SMN2KCNA5POLB | |
| SCHEMBL24312400 | 0.84 | CYP2D6 (0.38) | ADRB2ADRB1ADRB3CYP3A4HTT | |
| SCHEMBL10584182 | 0.84 | ADRB2 (0.35) | ADRB2ADRB1ADRB3CYP3A4HTT | |
| SCHEMBL3911872 | 0.84 | PTPRC (0.35) | ADRB2ADRB1ADRB3CYP3A4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116437927-A | Tetrahydrobenzodiazepine ketone compound and pharmaceutical application thereof | 日本烟草产业株式会社 | 2023-07-14 | — | — | CN | disclosed |
| US-20100113504-A1 | AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-05-06 | — | — | US | disclosed |
| EP-0657458-B1 | Protein kinase C inhibitors | LILLY CO ELI (US) | 2001-08-22 | — | — | EP | disclosed |
| US-6057440-A | AMINATION AND DEETHERIFICATION OF BISINDOLE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2000-05-02 | — | — | US | disclosed |
| US-5843935-A | Protein kinase C inhibitors | ELI LILLY AND COMPANY (US) | 1998-12-01 | — | — | US | disclosed |
| US-5821365-A | COMPOUNDS AS ENZYME INHIBITORS FOR KINASES FORMED BY REACTION OF AMINE WITH ANHYDRIDE GROUP TO FORM INDOLMALEIMIDE MACROCYCLES | ELI LILLY AND COMPANY (US) | 1998-10-13 | — | — | US | disclosed |
| US-5780461-A | ANTITUMOR AGENTS | ELI LILLY AND COMPANY (US) | 1998-07-14 | — | — | US | disclosed |
| US-5739322-A | INHIBITORS OF PROTEIN KINASE C IN MAMMALS | ELI LILLY AND COMPANY (US) | 1998-04-14 | — | — | US | disclosed |
| US-5719175-A | ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1998-02-17 | — | — | US | disclosed |
| US-5698578-A | BIS-INDOLEMALEIMIDE MACROCYCLE DERIVATIVES; TREATMENT OF DIABETES | ELI LILLY AND COMPANY (US) | 1997-12-16 | — | — | US | disclosed |
| US-5696108-A | ADMINISERING TO THE MAMMAL BIS-INDOLEMALEIMIDE MACROCYCLIC DERIVATIVE AS ANTIINFLAMMATORY AGENT | ELI LILLY AND COMPANY (US) | 1997-12-09 | — | — | US | disclosed |
| US-5674862-A | USING A BIS(INDOLEMALEIMIDE) MACROCYCLE DERIVATIVE | ELI LILLY AND COMPANY (US) | 1997-10-07 | — | — | US | disclosed |
| US-5624949-A | Protein kinase C inhibitors | ELI LILLY AND COMPANY (US) | 1997-04-29 | — | — | US | disclosed |
| US-5621098-A | ALKYLATION OF THE CORRESPONDING BISINDOLE COMPOUND; CYCLIZATION; PROTEIN C KINEASE INHIBITOR | ELI LILLY AND COMPANY (US) | 1997-04-15 | — | — | US | disclosed |
| WO-1996030048-A1 | PROTEIN KINASE C INHIBITORS | ELI LILLY AND COMPANY (US) | 1996-10-03 | — | — | WO | disclosed |
| EP-0735038-A1 | Protein kinase C inhibitors | ELI LILLY AND COMPANY (US) | 1996-10-02 | — | — | EP | disclosed |
| US-5552396-A | BIS-INDOLEMALEIMIDE MACROCYCLIC DERIVATIVES, | ELI LILLY AND COMPANY (US) | 1996-09-03 | — | — | US | disclosed |
| EP-0657458-A1 | Protein kinase C inhibitors | ELI LILLY AND COMPANY (US) | 1995-06-14 | — | — | EP | disclosed |
| US-4977279-A | Anticholesterol agents | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-12-11 | — | — | US | disclosed |
| US-4970313-A | Optically active 3-demethylmevalonic acid derivatives, and intermediates | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113504-A1 | AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS | HDAC3, HCCS, CCNH | ADRB2 2804/4885ADRB1 2014/4885ADRB3 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.